Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Rapid correction of low vitamin D status in nursing home residents 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. Medicare pay-for-reporting effort draws fire from frustrated doctors 5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment
Top Ten Searches
rheumatoid arthritis lupus polymyalgia sjogrens fibromyalgia amyloidosis vasculitis urate raynauds myositisYour Article Summary
See Latest ArticlesEfficacy and tolerability of urate lowering drugs in gout: A randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol
Annals of Rheumatic Diseases, 02/26/08
Reinders MK et al. - This study demonstrates a poor efficacy and tolerability profile of allopurinol 300 mg/day to attain a biochemical predefined target level of serum urate concentrations (sUr) <=0.30 mmol/l after 2-months treatment. In stage 2, benzbromarone 200 mg/day is more effective and better tolerated than probenecid 2000 mg/day.
Methods- Aim was to investigate the efficacy and tolerability of allopurinol and compare with benzbromarone and probenecid as second-choice treatment
- Prospective, multi-centre, open-label, randomised controlled trial of gout pts with normal renal function
- Pts were given 300 mg allopurinol for 2 mos (stage 1)
- When allopurinol was not tolerated or failed, pts were randomised to benzbromarone 200 mg/day or probenecid 2000 mg/day and treated for 2 mos (stage 2)
- 82/96 pts (85%) were eligible for the analysis of stage 1
- sUr concentrations decreased from baseline
- 20 pts (24%) attained target; 9 pts (11%) stopped allopurinol because of adverse drug reactions
- 62 pts were enrolled in stage 2: 27 pts received benzbromarone and 35 received probenecid
- With benzbromarone 22/24 pts (92%) were treated successfully
- Treatment success with probenecid was 20/31 pts (65%) compared with benzbromarone
- Compared with baseline values, sUr decreased 64[±9]% applying benzbromarone and decreased 50[±7]% applying probenecid
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Effect of minodronic acid hydrate on hip geometry in Japanese women with postmenopausal osteoporosis
Journal of Bone and Mineral Metabolism, 12/03/09
Dermatomyositis: current and future treatments
Expert Review of Dermatology, 12/03/09
Hypocomplementemic urticarial vasculitis syndrome
Current Rheumatology Reports, 12/03/09
Today in Gout and Hyperuricemia...keeping you current
Receive free subspecialty "5-minute updates" via email
Common Polymorphisms Influencing Serum Uric Acid Levels Contribute to Susceptibility to Gout, but Not to Coronary Artery Disease
PLoS ONE - Cardiovascular Disorders, 11/10/09
Associations of a nonsynonymous variant in SLC2A9 with gouty arthritis and uric acid levels in Han Chinese and Solomon Islanders
Annals of Rheumatic Diseases, 09/11/09
The modern management of gout
Rheumatology, 10/08/09
Sponsor
Article Search
Sponsor